Teva Pharma (TEVA) Tops Q2 EPS by 12c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
- Qualcomm shares fall on Intel warning and legal concerns
- Marvell Technology shares drop on Lumentum deal concerns
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Oracle shares drop on AI spending concerns and Microsoft criticism
- SpaceX stock drops on launch setback and sector selloff
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Teva Pharma (TEVA) Shares Surge on Proposed Opioid Settlement, Earnings Beat
July 27, 2022 11:44 AM EDTShares of Teva Pharma (NYSE: TEVA) jumped over 24% in early Wednesday trading following the announcement of its second-quarter results and an agreement, in principle, on a nationwide opioid settlement.
The company beat earnings and revenue forecasts, posting a profit of $0.68 per share on revenue of $3.79 billion. Analysts expected earnings per share of $0.56 on revenue of $3.78 billion.
However, it is the company's opioid settlement announcement that has caught the attention of... More



